Optimization of BP Control and Arterial Elasticity With Fixed Combination Therapy Perindopril and Amlodipine In Patients With Arterial Hypertension and Increased Pulse Wave Velocity

• Published in: Kardiologiia Vol. 57; no. 3; p. 31
• Main Authors: Nedogoda, S V, Konradi, A O, Zvartau, N E, Chumachek, E V, Ledyaeva, A A, Tsoma, V V, Salasyuk, A S, Judina, J S, Smirnova, V O, Khripaeva, V J, Palashkin, R V
• Format: Journal Article
• Language: Russian
• Published: Russia (Federation) 01.03.2017
• Subjects: Adult; Amlodipine - therapeutic use; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Antihypertensive Agents - therapeutic use; Blood Pressure - drug effects; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers - therapeutic use; Diuretics - therapeutic use; Drug Combinations; Female; Humans; Hypertension - drug therapy; Hypertension - physiopathology; Male; Middle Aged; Perindopril - therapeutic use; Pulse Wave Analysis; arterial hypertension; central blood pressure; pulse wave velocity; perindopril; amlodipine; augmentation index; combined antihypertensive therapy
• ISSN: 0022-9040
• DOI: 10.18565/cardio.2017.3.31-38

The aim of the study was to assess the possibility of fixed combination perindopril+amlodipine to improve arterial elesticity in patients with hypertension and high pulse wave velocity, despite previous combination antihypertensive therapy. In an open, multicenter, observational study duration of 24 weeks 80 patients were included, divided into 4 equal-sized groups, depending on initial antihypertensive therapy: Group 1 - the combination of ACE inhibitor and diuretic, Group 2 - the combination of ACE inhibitor and calcium channel blocker, Group 3 - the combination of diuretic and angiotensin receptor blocker, Group 4 - the combination of angiotensin receptor blocker and calcium antagonist. All patients underwent ambulatory BP monitoring, applanation tonometry (assessment of augmentation index and central blood pressure), pulse wave velocity measurement. According to the office BP measurements fixed combination perindopril+amlodipine provided the SBP reduction by 17.5%, 15.6%, 15, 6%, 15.5% and 17.7%, DBP reduction by 14.6%, 12.9%, 13.8%, respectively, in groups ACEI+D initial combination therapy, ACEI+AC initial combination therapy, ARB+D initial combination therapy, ARB+AC initial combination therapy. According ABPM data SBP has been decreased by 12.2%, 12.4%, 11.3%, 12.6% and DBP by 14.3%, 11.1%, 8.9%, 12.6%. The fixed combination perindopril+amlodipine reduced PWV by 25.2%, 21.6%, 23.1%, 23.0%, augmentation index by 43.4%, 48.9%, 41.5%, 38.3%, central SBP by 16.1%, 15.5%, 14.4%, 15.2%, the central DBP by 15.1%, 13.8%, 13.8%, 18.0% (p<0.01 vs. baseline). Fixed combination perindopril+amlodipine provides goal blood pressure control, improves arterial elasticity indexes (augmentation index, PWV, central blood pressure). Additional properties include reduction of BMI and lipid metabolism improving in patients initially treated with a combination antihypertensive therapy.